Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.

Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW.

Psychopharmacol Bull. 1998;34(3):373-82.

PMID:
9803771
2.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, BurĂ³n JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
3.

Economic outcomes associated with the use of risperidone in a naturalistic group practice setting.

Nightengale BS, Garrett L, Waugh S, Lawrence BJ, Andrus J.

Am J Manag Care. 1998 Mar;4(3):360-6.

4.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

5.

Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme.

Qiu Y, Fu AZ, Liu GG, Christensen DB.

Appl Health Econ Health Policy. 2010;8(3):167-77. doi: 10.2165/11318830-000000000-00000.

PMID:
20408601
6.

Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah.

Carter C, Stevens M, Durkin M.

Clin Ther. 1998 Mar-Apr;20(2):352-63.

PMID:
9589826
7.

Risperidone versus haloperidol: II. Cost-effectiveness.

Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I.

Clin Ther. 1998 Jan-Feb;20(1):196-213.

PMID:
9522115
8.

Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting.

Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL.

Psychopharmacol Bull. 1998;34(1):75-81.

PMID:
9564202
9.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
10.
11.

Impact of newer antipsychotics on outcomes in schizophrenia.

Keks NA.

Clin Ther. 1997 Jan-Feb;19(1):148-58; discussion 126-7.

PMID:
9083717
12.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
13.

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.

Gau SS, Chung CH, Gau CS.

J Clin Psychopharmacol. 2008 Jun;28(3):271-8. doi: 10.1097/JCP.0b013e3181723713.

PMID:
18480683
14.

Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA.

Clin Ther. 2008 Aug;30(8):1524-39; discussion 1506-7. doi: 10.1016/j.clinthera.2008.08.009.

PMID:
18803994
15.

Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.

Loosbrock DL, Zhao Z, Johnstone BM, Morris LS.

J Ment Health Policy Econ. 2003 Jun;6(2):67-75.

PMID:
14578539
16.

Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.

Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA.

J Clin Psychiatry. 1999 Dec;60(12):850-6.

PMID:
10665632
17.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
18.

Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group.

J Clin Psychiatry. 2012 May;73(5):696-702. doi: 10.4088/JCP.11m07070.

PMID:
22697193
20.

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.

Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout BA.

Curr Med Res Opin. 2008 Feb;24(2):349-58.

PMID:
18081988

Supplemental Content

Support Center